Roche
hemophilia drug wins fast-track FDA designation
ZURICH (Reuters) -
Roche said on Friday it had won breakthrough therapy
designation from the U.S. Food and
drug Administration for an experimental
hemophilia medicine, aiming for a piece of the $11 billion
hemophilia drug market.
